{"title":"Circulating biomarker profile and its diagnostic predictive utility in age-related macular degeneration.","authors":"Priya Battu, Suresh Sharma, Ramandeep Singh, Akshay Anand","doi":"10.1080/17520363.2026.2677199","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>We evaluated the serum expression profiles of proteins encoded by AMD-related genes in age-related macular degeneration patients and controls.</p><p><strong>Methods: </strong>In our case-control study, we employed Enzyme-linked immunosorbent assay (ELISA) to analyze the expression of Collagen type X alpha 1 chain (COL10A1), Transforming growth factor-beta receptor type 1(TGFβR1) and Tumor Necrosis Factor Receptor Superfamily (TNFRSF10A) in serum. We have also statistically analyzed the correlations among the biomarkers and further assessed their diagnostic potential using the least absolute shrinkage and selection operator (LASSO) regression.</p><p><strong>Results: </strong>Out of three evaluated serum protein levels, two were found to be significantly associated with AMD. The expression of COL10A1 was significantly upregulated (<i>p</i> < 0.0001), and TNFRSF10A was significantly downregulated (<i>p</i> < 0.0001) in AMD patients compared to controls. The LASSO logistic regression revealed that serum expression of COL10A1 and TNFRSF10A proteins can reliably differentiate AMD cases from controls with predictive accuracy of 87.3%.</p><p><strong>Conclusion: </strong>Our findings indicate that serum levels of COL10A1 and TNFRSF10A are significantly altered in AMD patients compared to controls. LASSO regression analyses further revealed that these proteins together have a strong ability to differentiate between AMD cases and controls, suggesting their potential as reliable biomarkers for risk prediction of AMD.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"409-418"},"PeriodicalIF":2.1000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13285555/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2026.2677199","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/3 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: We evaluated the serum expression profiles of proteins encoded by AMD-related genes in age-related macular degeneration patients and controls.
Methods: In our case-control study, we employed Enzyme-linked immunosorbent assay (ELISA) to analyze the expression of Collagen type X alpha 1 chain (COL10A1), Transforming growth factor-beta receptor type 1(TGFβR1) and Tumor Necrosis Factor Receptor Superfamily (TNFRSF10A) in serum. We have also statistically analyzed the correlations among the biomarkers and further assessed their diagnostic potential using the least absolute shrinkage and selection operator (LASSO) regression.
Results: Out of three evaluated serum protein levels, two were found to be significantly associated with AMD. The expression of COL10A1 was significantly upregulated (p < 0.0001), and TNFRSF10A was significantly downregulated (p < 0.0001) in AMD patients compared to controls. The LASSO logistic regression revealed that serum expression of COL10A1 and TNFRSF10A proteins can reliably differentiate AMD cases from controls with predictive accuracy of 87.3%.
Conclusion: Our findings indicate that serum levels of COL10A1 and TNFRSF10A are significantly altered in AMD patients compared to controls. LASSO regression analyses further revealed that these proteins together have a strong ability to differentiate between AMD cases and controls, suggesting their potential as reliable biomarkers for risk prediction of AMD.
期刊介绍：
Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory.
Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice.
As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications.
Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest.
Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
